TATA健康接获联交所额外复牌指引

Core Viewpoint - TATA Health (01255) has received a letter from the Stock Exchange regarding additional guidelines for the resumption of trading, which includes conducting an independent internal control review to demonstrate sufficient internal controls and procedures in compliance with listing rules [1] Group 1 - The company is required to perform an independent internal control review [1] - The review aims to ensure that the company has established adequate internal controls and procedures [1] - Compliance with listing rules is emphasized as a responsibility of the company [1]